Interventional Cardiology Resource Center Heartwire News High and Low

 
 
  • Alert FDA Okays Abiomed's Impella Heart Pump for Right Heart Failure The Impella RP heart pump is the only percutaneous temporary ventricular support device that is FDA approved as safe and effective for right heart failure, the company says.
  • ESC Data Bolster Dual Antithrombotic Therapy in AF PCI Patients A new study supports forgoing traditional triple antithrombotic therapy with aspirin for dual therapy with dabigatran and a P2Y12 inhibitor in patients with atrial fibrillation who've undergone PCI.
  • ESC ESC Guideline Update on Dual Antiplatelet Therapy in CAD The latest advice in this controversial area advocates a personalized-medicine approach based on ischemic vs bleeding risks, where each treatment and its duration is individualized as much as possible.
  • ESC Fentanyl in the Cath Lab: Routine but Risky? New data show the potent intravenous opiate weakens the antiplatelet effects of ticagrelor during PCI, challenging its routine and prophylactic use for cardiac catheterization and PCI in the US.
  • ESC New ESC Guideline on Peripheral Arterial Disease Patients with peripheral arterial disease often have comorbid cardiovascular and noncardiovascular conditions and should therefore be offered multidisciplinary care, recommend new European guidelines.
  • ESC New ESC Guideline on Acute ST-Segment Elevation MI The new guidelines update the 2012 version and contain multiple summary tables for each section, as well as clear definitions of terms: "door-to-balloon" is out, "FMC" and "MINOCA" are in.
  • ESC MAUDE: Post-TAVR Leaflet Thrombosis Not Benign While post-TAVR leaflet thrombosis can cause valve dysfunction or even cardiogenic shock and death, the question remains whether there's justification for routine anticoagulation given its inherent risks.
  • ESC Platelet Testing Guides Prasugrel-to-Clopidogrel Switch Post-ACS The TROPICAL-ACS trial has validated a new "deescalation" regimen of antiplatelet therapy that could be applicable to patients unsuitable for long-term potent therapy due to bleeding or affordability concerns.
  • Alert Abbott Halts Sales of First Gen Bioresorbable Absorb Stent Due to low sales, Abbott will discontinue all sizes of Absorb Bioresorbable Vascular Scaffold System and Absorb GT1 Bioresorbable Vascular Scaffold System.
  • ESC Routine LAA Closure at Heart Surgery: Support From LAACS Closing off the left-atrial appendage at CABG or valve surgery, widely done without much of an evidence base, seemed to protect against strokes, symptomatic or silent, in a small randomized trial.
  • ESC STEMI Survival Gains Seen After Early Aldosterone Inhibition Starting aldosterone inhibitors early after acute STEMI may not be just for patients with LV dysfunction, suggests an analysis based on the ALBATROSS and REMINDER trials.
  • ESC Nonagenarians 'Good Candidates' for TAVI Surgery Severe aortic-stenosis patients aged 90 years or older can be candidates for transcatheter aortic-valve implantation, with similar outcomes to those in younger patients, researchers say.
  • ESC BIOFLOW-V: Orsiro Bests Workhorse Xience at 12 Months The biodegradable-polymer Orsiro sirolimus-eluting stent proved superior to the durable-polymer Xience everolimus-eluting stent for 12-month target lesion failure and MI in patients with up to three native de novo or restenotic coronary artery lesions.
  • ESC No Gain With Upstream P2Y12 Inhibitors in STEMI PCI A large observational study contradicts US and European STEMI guideline recommendations to treat STEMI patients with P2Y12 receptor inhibitors before primary PCI.
  • ESC Ticagrelor for DAPT Again Questioned in Modern-Era PCI for ACS In CHANGE-DAPT, more bleeds than clopidogrel without a clinical upside: Maybe ticagrelor isn't the best for dual antiplatelet therapy in PCI for ACS, given the prowess of modern drug-eluting stents, researchers say.
  • ESC ESC Rapid Rule-In, Rule-Out Algorithm for NSTEMI Safe, Accurate The findings "should give confidence in the high safety and applicability" of the European Society of Cardiology 0/1-hour algorithm to rule in or rule out non-ST-segment-elevation MI, says the study's lead author.
  • ESC Sildenafil Warning in Pulmonary Hypertension After Valve Surgery Clinicians should not assume that sildenafil is beneficial in pulmonary hypertension following valve surgery, warn Spanish researchers after finding the drug doubles clinical events in these patients.
  • ESC Underweight Patients Fare Worse After Heart Catheterization Registry-based research reinforces the concept of an "obesity paradox," but it is also "really striking how poorly underweight patients do," researchers say.
  • ESC Gender Gap Reduced for Post-AMI In-Hospital Mortality Women suffering acute MI have experienced great reductions in in-hospital mortality over the past 20 years that have virtually eliminated the gender survival gap, Swiss registry data suggest.
  • ESC COMPASS: Rivaroxaban Success in Secondary CV Prevention The combination of a low dose of the factor Xa inhibitor rivaroxaban in combination with aspirin was associated with a reduction in ischemic events and mortality and a superior net clinical benefit, balancing the bleeding risk in patients with stable atherosclerotic disease.